Novavax received FDA emergency use authorization for its updated 2026–2027 COVID-19 vaccine, positioning it as a key non-mRNA option. This, combined with raised full-year revenue guidance and a strategic pivot towards licensing, is driving significant positive momentum for the stock.
Novavax's stock is surging due to two primary catalysts: the FDA's emergency use authorization for its updated 2026–2027 COVID-19 vaccine and a strong Q2 financial update that included raised full-year revenue guidance and a strategic pivot towards licensing. This FDA clearance is crucial as it establishes Novavax as a primary non-mRNA alternative for the upcoming vaccination season, directly competing with Pfizer/BioNTech and Moderna. The strategic shift, highlighted by CEO John C. Jacobs, aims to extend the company's financial runway and optimize its cost structure, suggesting a more sustainable business model. While the broader vaccine sector saw a boost from Merck and Moderna's cancer vaccine breakthrough, Novavax's specific news provides a direct, positive short-term catalyst for its shares, with long-term implications tied to successful commercial delivery and the effectiveness of its strategic pivot.